9877 logo

Jenscare Scientific Co., Ltd. Stock Price

SEHK:9877 Community·HK$3.9b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

9877 Share Price Performance

HK$9.44
5.21 (123.17%)
HK$9.44
5.21 (123.17%)
Price HK$9.44

9877 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Mediocre balance sheet with minimal risk.

1 Risk
0 Rewards

Jenscare Scientific Co., Ltd. Key Details

CN¥90.6m

Revenue

CN¥8.1m

Cost of Revenue

CN¥82.5m

Gross Profit

CN¥353.7m

Other Expenses

-CN¥271.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.65
91.09%
-299.41%
5.7%
View Full Analysis

About 9877

Founded
2011
Employees
174
CEO
Fei Pan
WebsiteView website
www.jenscare.com

Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of interventional products for the treatment of structural heart diseases in the People’s Republic of China. It offers LuX-Valve and LuX-Valve Plus, a transcatheter tricuspid valve replacement (TTVR) product for the treatment of severe tricuspid regurgitation and high surgical risk; KenFlex, a transcatheter aortic valve intervention (TAVR) repair system product for the treatment of aortic valve regurgitation; and Ken-Valve, a TRVR system for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops JensClip, a clip-based transcatheter mitral valve intervention (TMVR) repair system to treat patients with severe mitral regurgitation; JensRelive, a TMVR system to treat patients with severe mitral regurgitation and replace dysfunctional primary mitral valves without undergoing routine thoracotomy surgery; and SimuLock, a bionics left atrial appendage occluder system for cardiogenic stroke prevention. In addition, it offers platform technologies/accessories comprising introducer kit, JeniGal anti-calcification technology, dry-tissue technology and polymer leaflet technology; and engages in consulting and investment activities. The company was incorporated in 2011 and is headquartered in Ningbo, the People’s Republic of China.

Recent 9877 News & Updates

Recent updates

No updates